뒤로
Viridian Therapeutics Inc(VRDN) 가격
VRDN 주가 차트
VRDN 수입
Viridian Therapeutics Inc
$29.25
0.27%
$0.07
종가: Feb 06, 16:00:00 GMT-5
$29.25
0%
$0
애프터마켓: Feb 06, 20:00:00 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-05
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
VRDN의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Viridian Therapeutics Inc VRDN의 지난 분기 매출 실적은 어땠나요?
Viridian Therapeutics Inc의 매출 추정치는 얼마인가요?
Viridian Therapeutics Inc의 수익 품질 점수는 얼마인가요?
Viridian Therapeutics Inc는 언제 수익을 보고하나요?
Viridian Therapeutics Inc의 예상 수익은 얼마인가요?
Viridian Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$29.17
시가
$30.14
일일 범위
$28.94 - $30.16
52주 범위
$9.9 - $34.29
거래량
1.4M
평균 거래량
1.5M
EPS(TTM)
-3.72
배당수익률
--
시가총액
$2.7B
VRDN란 무엇인가요?
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 143 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. The company is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.